<DOC>
	<DOCNO>NCT00737594</DOCNO>
	<brief_summary>The primary purpose study determine efficacy safety cobiprostone ( two dose level ) compare placebo lower portal hypertension .</brief_summary>
	<brief_title>Efficacy Safety Cobiprostone Patients With Portal Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<criteria>Patient &gt; = 18 year age . Patient clinical and/or pathological diagnosis intrahepatic portal hypertension . Patient clinical diagnosis cirrhosis . Patient undergone variceal banding . Patient ChildPugh score &gt; 12 . Patient portal hypertension result hepatic vein obstruction , portal vein occlusion , schistosomiasis , portal vein thrombosis , splenic vein thrombosis , BuddChiari syndrome . Variceal band procedure perform within 1 month screen visit . Patient active recurrent variceal bleeding , variceal bleeding within 12 week prior screen . Patient unwilling discontinue use vasoactive drug screen visit end study . Patient hepatocellular carcinoma medically treat advanced . Patient impair renal function ( i.e. , serum creatinine concentration &gt; 1.8 mg/dl ) Patient history liver transplant , expect receive liver transplant study period . Patient undergone gastrointestinal abdominal surgical procedure within 90 day prior Screening Visit , bowel resection time .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>